Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arqit Quantum Inc (ARQQ) vs Cytokinetics Inc (CYTK) Price & Performance

Arqit Quantum IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Arqit Quantum Inc vs Cytokinetics Inc — how do they compare? Arqit Quantum Inc trades at $23.67 (market cap $424.79M), while Cytokinetics Inc trades at $77.71 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 25× Arqit Quantum Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.

ARQQCYTK
Market Cap
$424.79M$10.63B
Sector
TechnologyTechnology
52-Week High
$58.27$87.26
52-Week Low
$11.78$34.31
Enterprise Value
$398.10M$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arqit Quantum Inc

No Aura AI signal available yet.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK